Scripx Pharmacy & Health
Evolving the access and affordability of medications via tech and automation
Overview
Raised: $45,951
Rolling Commitments ($USD)
02/04/2023
$287
107
2021
Healthcare & Pharmaceuticals
HealthTech
B2C
Low
Low
Summary Profit and Loss Statement
Most Recent Year | Prior Year | |
---|---|---|
Revenue |
$1,910,831 |
$557,891 |
COGS |
$1,928,213 |
$453,488 |
Tax |
$0 |
$0 |
| ||
| ||
Net Income |
$-372,099 |
$-126,692 |
Summary Balance Sheet
Most Recent Year | Prior Year | |
---|---|---|
Cash |
$63,513 |
$6,579 |
Accounts Receivable |
$119,000 |
$85,476 |
Total Assets |
$940,877 |
$218,821 |
Short-Term Debt |
$333,389 |
$131,483 |
Long-Term Debt |
$761,455 |
$7,872 |
Total Liabilities |
$1,094,844 |
$139,355 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Scripx is following in the footsteps of NowRx and Capsule. It’s a Dallas-based virtual pharmacy operating within the Dallas-Fort Worth metropolitan area. Scripx offers prescription fulfillment and delivery as well as limited telehealth services. Customers can use the company’s mobile app to upload insurance documents, track their prescriptions, and order refills. But there are a few things investors should consider before investing in a duplicative company like Scripx. Rather than blazing a new trail, it’s following the drug delivery service playbook created by NowRX and Capsule. And that comes with its own mix of advantages and disadvantages.